Compare Stocks → The new financial threat that could wipe out millions… (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABEONASDAQ:ETONNASDAQ:PHASNASDAQ:SBBP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$4.40-3.5%$6.84$2.83▼$9.01$120.34M1.59545,468 shs455,891 shsETONEton Pharmaceuticals$3.72$3.75$2.42▼$5.81$95.57M1.1965,162 shs57,822 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shsN/ASBBPStrongbridge Biopharma$2.00$2.09$1.85▼$4.26$135.66M1.58866,464 shs684,684 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-4.60%+10.14%-38.71%-6.94%+45.69%ETONEton Pharmaceuticals-0.80%+6.29%+3.62%-18.78%+7.20%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%-16.67%SBBPStrongbridge Biopharma0.00%0.00%0.00%0.00%0.00%The new financial threat that could wipe out millions… (Ad)During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.Pay close attention to this important videoMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics4.3303 of 5 stars3.51.00.04.53.73.30.6ETONEton Pharmaceuticals2.3461 of 5 stars3.55.00.00.02.30.80.0PHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics3.00Buy$36.00718.18% UpsideETONEton Pharmaceuticals3.00Buy$9.00141.94% UpsidePHASPhaseBio PharmaceuticalsN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest SBBP, ETON, PHAS, and ABEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2024ETONEton PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.004/23/2024ABEOAbeona TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$36.00(Data available from 5/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M34.38N/AN/A$0.60 per share7.33ETONEton Pharmaceuticals$31.64M3.02N/AN/A$0.60 per share6.20PHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00SBBPStrongbridge Biopharma$30.73M4.41N/AN/A$0.98 per share2.04Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$54.19M-$2.58N/AN/AN/AN/A-280.58%-76.90%5/9/2024 (Estimated)ETONEton Pharmaceuticals-$940K-$0.03N/A∞N/A-2.96%-6.21%-3.17%5/9/2024 (Confirmed)PHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/ASBBPStrongbridge Biopharma-$45.08M-$0.78N/AN/AN/A-115.67%-66.82%-36.21%N/ALatest SBBP, ETON, PHAS, and ABEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024N/AETONEton Pharmaceuticals-$0.02N/A+$0.02N/AN/AN/A 3/18/2024Q4 2023ABEOAbeona Therapeutics-$0.51-$0.64-$0.13-$0.64N/AN/A3/14/2024Q4 2023ETONEton Pharmaceuticals-$0.04-$0.09-$0.05-$0.09$7.70 million$7.31 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona TherapeuticsN/A4.154.15ETONEton PharmaceuticalsN/A1.651.60PHASPhaseBio PharmaceuticalsN/A0.470.47SBBPStrongbridge Biopharma0.383.002.95OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%ETONEton Pharmaceuticals27.86%PHASPhaseBio Pharmaceuticals49.02%SBBPStrongbridge Biopharma52.03%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.30%ETONEton Pharmaceuticals13.16%PHASPhaseBio Pharmaceuticals9.90%SBBPStrongbridge Biopharma5.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona TherapeuticsN/A27.35 million25.91 millionOptionableETONEton Pharmaceuticals3025.69 million22.31 millionOptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableSBBPStrongbridge Biopharma7267.83 millionN/AOptionableSBBP, ETON, PHAS, and ABEO HeadlinesSourceHeadlineRising Investment in Patient Support Drives a Greater Biopharma Focus on Measurementfiercepharma.com - March 5 at 7:51 AMMatinas BioPharma Holdings Inc (MTNB)investing.com - February 10 at 12:33 PMLytix Biopharma As Share Price (LYTIX.OL)lse.co.uk - November 15 at 2:21 AMAmbrx Biopharma Inc AMAMmorningstar.com - November 4 at 7:36 PMBiopharma’s rapid transition to omnichannel marketingpharmaphorum.com - September 11 at 9:18 AMHILS Hillstream BioPharma, Inc.seekingalpha.com - August 19 at 3:55 PMABUS - Arbutus Biopharma Corporationfinance.yahoo.com - July 1 at 12:38 PMThe Nominees for Best Biopharma CEO of 2015 Are...thestreet.com - April 25 at 8:23 AMDay One Biopharma Shares Rise 13% After Positive Topline Results for Tovorafenibmarketwatch.com - January 11 at 9:43 PMBiopharma Soars to the Computational Cloudsgenengnews.com - October 9 at 12:47 PMAccord BioPharma Partners with StoryMD to Deliver Advanced Prostate Cancer Educational Content to Clinicians and Patientsmarkets.businessinsider.com - September 22 at 10:04 AMStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by ...apnews.com - September 23 at 5:49 PMStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.finance.yahoo.com - September 23 at 5:49 PMPress Release: Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharmasharecast.com - September 14 at 5:56 PMXeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharmastockhouse.com - September 14 at 5:56 PMStrongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris ...apnews.com - September 9 at 12:31 PMLeading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders ...apnews.com - August 31 at 7:54 AMSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote "FOR" the Transaction With Xeristmcnet.com - August 31 at 7:54 AMSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xerisfinance.yahoo.com - August 31 at 7:54 AMStrongbridge Biopharma plc (NASDAQ: SBBP) Have Dropped -20.16% YTD, What Will Happen Nextmarketingsentinel.com - August 14 at 7:50 AMStrongbridge Biopharma: Q2 Earnings Snapshotsfgate.com - August 5 at 8:43 AMStrongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 5 at 8:43 AMStrongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statementfinance.yahoo.com - August 2 at 9:34 AMStrongbridge Biopharma plc (NASDAQ:SBBP) Shares Plunges -8.08% In A Week – But Can It Keep Rising?marketingsentinel.com - July 31 at 9:50 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? April 9, 2024 6:07 AMView Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? 3 Stocks Getting Boosted by AnalystsMay 6, 2024 6:05 AMView 3 Stocks Getting Boosted by AnalystsPenny Stock Quantum-Si Incorporated Readies For Lift-OffApril 9, 2024 7:14 AMView Penny Stock Quantum-Si Incorporated Readies For Lift-OffAll Headlines Company DescriptionsAbeona TherapeuticsNASDAQ:ABEOAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Eton PharmaceuticalsNASDAQ:ETONEton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.PhaseBio PharmaceuticalsNASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.Strongbridge BiopharmaNASDAQ:SBBPStrongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.